Gary Sopher

Articles by Gary Sopher

119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Breast Cancer (ABC) Treated With Ribociclib (RIB) + Fulvestrant (FUL): A Subgroup Analysis of Patients With Invasive Lobular Carcinoma (ILC)

ByMichelino De Laurentiis,Jason Mouabbi,Seock-Ah Im,Megan Kruse, MD,Stephen Chia,Sara Brucker,Cristian Villanueva,Guy Jerusalem,Melissa Gao,Gary Sopher,Jiwen Wu,Juan Pablo Zarate,J. Thaddeus Beck

May 11th 2026

18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

ByRadhika Appaya,Sarah Sammons, MD,Priyanka Sharma, MD,Yara Abdou,VK Gadi, MD, PhD,Taavy A. Miller,Spencer S. Langerman,Dominick Latremouille-Viau,Annie Guerin,Carmine Rossi,Emily McGovern,Gary Sopher,Vamsi Bollu,Natalia Bolotova,Şerban R. Iorga,Liz Santarsiero,Susan Dent, MD

June 30th 2025

Latest Updated Articles

Trending on CancerNetwork

How Well Does Radiotherapy Pair With Dual PD-1/LAG-3 Blockade in NSCLC?

Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma

Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer

FDA OKs Pirtobrutinib in Frontline CLL/SLL

NDA Submission Begins for Zipalertinib Combo in First-Line EGFR+ NSCLC